Furthermore, there were no differences in the mutational burden and transcriptional profile of tumor cells, respectively assessed by whole-exome sequencing (n = 23) and RNA-seq (n = 102), between patients with <0.3 and ≥0.3 CD27−:CD27+ratio (Fig. S10). This evidence concerns the gene CD27 and neoplasm.